File:Prophylactic-versus-Therapeutic-Fingolimod-Restoration-of-Presynaptic-Defects-in-Mice-Suffering-pone.0170825.g007.jpg

English: Fig 2. Effects of in vivo prophylactic fingolimod on demyelination and inflammation in the spinal cord of EAE mice at the acute stage of disease. On day 21 post EAE induction, spinal cord sections were analyzed. (A, B) Luxol Fast Blue stained myelin in blue and revealed demyelinated areas; (C, D) Hematoxylin/Eosin stained infiltrated cells and tissue components. Representative images at 10X (A, C) and 20X (B, D) magnification of white matter of anterior spinal cord of each group are shown. (E) CD3-positive cells in spinal cord. Sections were immune-stained with the anti-CD3 antibody (red) to recognize T-cells and with DAPI (blue) to identify cell nuclei. Representative images of 20X magnification of the spinal cord section. (F) The number of CD3-positive cells/mm2 in the spinal cord of mice of each treatment-group is reported. * p < 0.05 versus control untreated mice; ° p < 0.05 versus untreated EAE mice. Histochemical analysis and CD3 staining were performed on slices from control untreated mice (n = 5), from control 0.3 mg /kg fingolimod-treated mice (n = 4), from EAE untreated mice (n = 5), from EAE 0.3 mg /kg fingolimod-treated mice (n = 5).